Partnering
Hu-PAC™ an unencumbered and independent platform
The Hu-PAC™ platform is unencumbered by patent or licensing restrictions and can be used to develop antibodies against any antigen target.
There are a number of partnering options available with 4-Antibody:
- Out-licensing or partnered development of Hu-PAC™ fully human antibodies in the 4-Antibody pipeline.
- Joint initiation of co-development projects for validated targets.
- Non-exclusive Licensing of the Hu-PAC™ platform for in-house discovery of programmes against any target.